LLY

1,139.44

-1.38%↓

JNJ

235.89

+2.07%↑

ABBV

224.86

+1.61%↑

UNH

409.98

+1.81%↑

MRK

119.57

+0.27%↑

LLY

1,139.44

-1.38%↓

JNJ

235.89

+2.07%↑

ABBV

224.86

+1.61%↑

UNH

409.98

+1.81%↑

MRK

119.57

+0.27%↑

LLY

1,139.44

-1.38%↓

JNJ

235.89

+2.07%↑

ABBV

224.86

+1.61%↑

UNH

409.98

+1.81%↑

MRK

119.57

+0.27%↑

LLY

1,139.44

-1.38%↓

JNJ

235.89

+2.07%↑

ABBV

224.86

+1.61%↑

UNH

409.98

+1.81%↑

MRK

119.57

+0.27%↑

LLY

1,139.44

-1.38%↓

JNJ

235.89

+2.07%↑

ABBV

224.86

+1.61%↑

UNH

409.98

+1.81%↑

MRK

119.57

+0.27%↑

Home・Aandelen Lijst・Avita Therapeutics Inc

Avita Therapeutics Inc

Open

3.96 -4.35

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.96

Max

4.22

Belangrijke statistieken
By Trading Economics
Inkomsten	1M -11M
Verkoop	1.6M 19M
EPS	-0.48
Winstmarge	-55.119
Werknemers	226
EBITDA	1.1M -8.6M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+71.53% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	308K 135M
Vorige openingsprijs	8.31
Vorige sluitingsprijs	3.96

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 jun 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 jun 2026, 15:41 UTC

Belangrijke Marktbewegers

American Battery Shares Jump on Energy Department Victory

8 jun 2026, 23:46 UTC

Marktinformatie

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 jun 2026, 23:37 UTC

Marktinformatie

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 jun 2026, 23:25 UTC

Marktinformatie

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 jun 2026, 23:25 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jun 2026, 21:57 UTC

Acquisities, Fusies, Overnames

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 jun 2026, 21:56 UTC

Acquisities, Fusies, Overnames

Salesforce Agrees to Buy m3ter

8 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

8 jun 2026, 19:22 UTC

Marktinformatie

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 jun 2026, 19:01 UTC

Marktinformatie

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 jun 2026, 18:52 UTC

Marktinformatie

Global Energy Roundup: Market Talk

8 jun 2026, 18:52 UTC

Marktinformatie

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 jun 2026, 18:17 UTC

Marktinformatie

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 jun 2026, 17:32 UTC

Marktinformatie

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 jun 2026, 17:29 UTC

Marktinformatie

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 jun 2026, 17:29 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 jun 2026, 16:55 UTC

Acquisities, Fusies, Overnames

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 jun 2026, 16:54 UTC

Acquisities, Fusies, Overnames

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 jun 2026, 16:40 UTC

Marktinformatie

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 jun 2026, 16:31 UTC

Marktinformatie

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 jun 2026, 16:27 UTC

Marktinformatie

Mexican Inflation Seen Easing in May -- Market Talk

8 jun 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 jun 2026, 16:03 UTC

Acquisities, Fusies, Overnames

Orange Bought Stake From Lorca

8 jun 2026, 16:01 UTC

Acquisities, Fusies, Overnames

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 jun 2026, 16:01 UTC

Acquisities, Fusies, Overnames

Orange Acquires 100% Ownership of MasOrange

8 jun 2026, 15:58 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jun 2026, 15:58 UTC

Marktinformatie

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 jun 2026, 15:55 UTC

Marktinformatie

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 jun 2026, 15:41 UTC

Marktinformatie

Gold Falls Below 200-Day Moving Average -- Market Talk

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

71.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 7.17 USD 71.53%

Hoogste 10 USD

Laagste 5.5 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Avita Therapeutics Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.